跳转至内容
Merck
CN

M-144

MDAI hydrochloride solution

100 μg/mL in acetonitrile: water (9:1) with 5% 1 M HCl (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C10H11NO2 · HCl
化学文摘社编号:
分子量:
213.66
NACRES:
NA.24
UNSPSC Code:
41116107
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule E (Switzerland); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

concentration

100 μg/mL in acetonitrile: water (9:1) with 5% 1 M HCl (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−70°C

SMILES string

Cl.NC1Cc2cc3OCOc3cc2C1

InChI

1S/C10H11NO2.ClH/c11-8-1-6-3-9-10(13-5-12-9)4-7(6)2-8;/h3-4,8H,1-2,5,11H2;1H

InChI key

DEZYWEZDXRXACY-UHFFFAOYSA-N

General description

MDAI, or 5,6-Methylenedioxy-2-aminoindane, is a new stimulant and club/designer drug with significant cases of abuse reported in Asia, Europe and the US. Sold over the Internet as a “bath salt,” MDAI is a potential successor to mephedrone as the next legal high drug.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany


pictograms

FlameExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

55.4 °F - closed cup

flash_point_c

13 °C - closed cup

法规信息

监管及禁止进口产品

此项目有



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

Bath Salts in Urine - Supel-Select SCX SPE and Ascentis Express HILIC Application Note


Roland P Archer et al.
Drug testing and analysis, 3(7-8), 505-514 (2011-07-12)
Historically, the appearance of new psychoactive materials (and hence the requirement for new reference standards) has been relatively slow. This position has now changed, with 101 new psychoactive substances reported to EMCDDA-Europol since 2006. The newly reported materials, and associated
Cathal T Gallagher et al.
Human psychopharmacology, 27(2), 106-112 (2012-03-06)
The fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the UK in April 2010, and almost immediately, MDAI was widely
R Oberlender et al.
The Journal of pharmacology and experimental therapeutics, 255(3), 1098-1106 (1990-12-01)
The stimulus properties of 3,4-methylenedioxymethamphetamine (MDMA)-like compounds were studied in rats trained to discriminate saline from (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine [(+)-MBDB] hydrochloride (7.18 mumol/kg; 1.75 mg/kg), the alpha-ethyl homolog of MDMA. In previous experiments with (+)-MBDB as a test drug, complete substitution was



全球贸易项目编号

货号GTIN
M-144-1ML04061833986042